Abstract
The extraordinary success of imatinib in gastrointestinal stromal tumor (GIST) represents a model for molecularly targeted therapy of solid tumors. Research is currently going to identify the molecular basis of mechanisms of action and drug resistance. For the optimal management of the patients treated, a multidisciplinary approach, including medical oncologists, surgeons, pathologists, and radiologists is needed. In this article, we reviewed recent advances in the clinical management of GIST patients treated with imatinib, and in the knowledge of the molecular mechanisms that are basic to imatinib effects.
Keywords: Imatinib, KIT, Gastrointestinal stromal tumor, GIST, Imaging
Reviews on Recent Clinical Trials
Title: Critical Update and Emerging Trends in Imatinib Treatment for Gastrointestinal Stromal Tumor
Volume: 2 Issue: 1
Author(s): Ugo De Giorgi, Alberto Pupi, Gina Turrisi, Iolanda Montenora, Stefano Morini, Mozghan Fayyaz, Michele De Simone and Giammaria Fiorentini
Affiliation:
Keywords: Imatinib, KIT, Gastrointestinal stromal tumor, GIST, Imaging
Abstract: The extraordinary success of imatinib in gastrointestinal stromal tumor (GIST) represents a model for molecularly targeted therapy of solid tumors. Research is currently going to identify the molecular basis of mechanisms of action and drug resistance. For the optimal management of the patients treated, a multidisciplinary approach, including medical oncologists, surgeons, pathologists, and radiologists is needed. In this article, we reviewed recent advances in the clinical management of GIST patients treated with imatinib, and in the knowledge of the molecular mechanisms that are basic to imatinib effects.
Export Options
About this article
Cite this article as:
De Giorgi Ugo, Pupi Alberto, Turrisi Gina, Montenora Iolanda, Morini Stefano, Fayyaz Mozghan, De Simone Michele and Fiorentini Giammaria, Critical Update and Emerging Trends in Imatinib Treatment for Gastrointestinal Stromal Tumor, Reviews on Recent Clinical Trials 2007; 2 (1) . https://dx.doi.org/10.2174/157488707779318143
DOI https://dx.doi.org/10.2174/157488707779318143 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Advances in Regulating Tumorigenicity and Metastasis of Cancer Through TrkB Signaling
Current Cancer Drug Targets Nitric Oxide: Cancer Target or Anticancer Agent?
Current Cancer Drug Targets Alpha-1-Adrenergic Receptor Blockade Modifies Insulin-Regulated Aminopeptidase (IRAP) Activity in Rat Prostate and Modulates Oxytocin Functions
Drug Metabolism Letters Pegylation and Cell Based Bioassay of Human Interferon-α2b Along its Docking Studies and Effect on Plasma Half-Life
Protein & Peptide Letters Tumor Targeting Using Radiolabeled Antibodies for Image-Guided Drug Delivery
Current Drug Targets Lipid-based Nanocarriers for siRNA Delivery: Challenges, Strategies and the Lessons Learned from the DODAX: MO Liposomal System
Current Drug Targets Small Molecule Inhibitors of Multidrug Resistance Gene (MDR1) Expression: Preclinical Evaluation and Mechanisms of Action
Current Cancer Drug Targets Mesenchymal Stem Cells: An Emerging Tool for Cancer Targeting and Therapy
Current Stem Cell Research & Therapy Potential Drug Targets on the HIV-1 Envelope Glycoproteins, gp120 and gp41
Current Pharmaceutical Design FTD and ALS: A Tale of Two Diseases
Current Alzheimer Research Oxocarbon Acids and their Derivatives in Biological and Medicinal Chemistry
Current Medicinal Chemistry Targeting the Programmed Cell Death-1 Pathway in Genitourinary Tumors: Current Progress and Future Perspectives
Current Drug Metabolism Liver Fibrosis Assessment in a Cohort of Greek HIV Mono-Infected Patients by Non-Invasive Biomarkers
Current HIV Research E3 Ubiquitin Ligases as Molecular Targets in Human Oral Cancers
Current Cancer Drug Targets Antibody Gene Therapy: Getting Closer to Clinical Application?
Current Gene Therapy A Link Between Chemical Structure and Biological Activity in Triterpenoids
Recent Patents on Anti-Cancer Drug Discovery Dendritic Cells for Active Anti-Cancer Immunotherapy: Targeting Activation Pathways Through Genetic Modification
Endocrine, Metabolic & Immune Disorders - Drug Targets Natural Products Targeting Autophagy via the PI3K/Akt/mTOR Pathway as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry L-carnitine: Searching for New Therapeutic Strategy for Sepsis Management
Current Medicinal Chemistry Medicinal Plants and Cancer Chemoprevention
Current Drug Metabolism